Journal of the International AIDS Society: an important step forward by unknown
BioMed Central
Journal of the International AIDS 
Society
ssOpen AcceEditorial
Journal of the International AIDS Society: an important step 
forward
Mark A Wainberg1, Elly Katabira2 and Shirin Heidari*3
Address: 1McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada, 2Makerere Medical School, Kampala, Uganda and 
3International AIDS Society, Geneva, Switzerland
Email: Mark A Wainberg - mark.wainberg@mcgill.ca; Elly Katabira - katabira@imul.com; Shirin Heidari* - shirin.heidari@iasociety.org
* Corresponding author    
Abstract
This editorial welcomes readers to the launch of Journal of the International AIDS society.
Editorial
Journal of the International AIDS Society (JIAS) was re-
launched at the International AIDS Conference in Mexico
in August 2008.
After four years of fruitful collaboration with Medscape
Journal of Medicine, which allowed JIAS to operate and
grow under its umbrella, we have reached the time when
we are able to become an independent journal and con-
tinue with this success. Our gratitude must go to our
former partner Medscape for this collaboration, which we
now hope to continue in new forms.
Journal of the International AIDS Society (JIAS) is now
proud to be associated with BioMed Central as its new
publisher.
BioMed Central has a long history of successful publica-
tions in a wide array of disciplines in medical science.
They are professional and have attained high levels of suc-
cess by providing an artful combination of rapid peer
review, open access, and a professional staff that strives at
all times to help journals to sustain high quality publica-
tions.
The achievements of BioMed Central in the field of HIV/
AIDS in recent years is perhaps best illustrated by the suc-
cess of two sister journals; Retrovirology and AIDS Research
and Therapy, journals with which JIAS is committed to
work with closely in the future.
An important key to the success of medical journals is the
ability to engage serious and well-respected reviewers who
are willing to donate their time to assist in the peer review
process. This is a formula for success that JIAS will now
adopt to attain the goals that we, the Editors-in-Chief and
our sponsor, the International AIDS Society, have set.
As in the past, we will give priority to articles that are sub-
mitted by authors in developing countries and will insist
that all articles accepted for publication be of high quality.
In order to maintain a high standard of publication, JIAS
is committed to provide mentorship to authors as a means
of helping them improve the quality of submitted manu-
scripts.
We hope that we will receive articles on the all important
topic of HIV clinical trials, which now are, to an increasing
extent, being carried out in developing country settings.
This is a reflection of where the great burden of HIV infec-
tion in the world actually is, as well as the fact that an
insufficient number of patients available for enrollment
into large scale clinical trials currently reside in developed
countries. Many new drugs, that are now being tested for
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the first time in either naive or experienced populations,
are increasingly being studied in developing country set-
tings. We hope our journal will create a platform for dis-
semination of the results of these trials during the coming
years.
Of course we also hope to attract excellent manuscripts in
areas of research that may be related tangentially to clini-
cal trials. As an example, the study of the prevalence of
drug resistance mutations in different countries is a topic
of widespread interest as is the extent to which sexual
transmission of mutations associated with drug resistance
might take place. The occurrence and transmission of such
mutations is, of course, an unfortunate yet inevitable con-
sequence of the increasing availability of antiretroviral
drugs (ARVs). Frequently, different patterns of such trans-
missions may occur in different countries based on pat-
terns of drug use. It will be important to document such
differences. This is but one example of research that will
be encouraged by JIAS for potential publication.
The issue of drug resistance clearly has important overlaps
with the epidemiology of HIV disease in both developed
and developing country settings. Every effort will be made
to encourage submissions of manuscripts from epidemi-
ologists who are anxious to describe the state of the HIV
epidemic in a variety of developing and developed coun-
try settings.
We welcome commentary pieces on important topics.
These may include such subjects as government policies in
regard to access to antiretroviral drugs and whether or not
appropriate efforts are being made to promote use or not
of generic products. We will also welcome articles in the
social sciences and examples of topics that might be cov-
ered include attitudes towards prevention trial research in
the aftermath of the failures of phase 3 clinical trials
involving potential vaccines and microbicides.
Commentary articles will also be welcome on the issue of
government policy toward encouragement of safe sex
practices, as will articles on the ethics of various research
approaches involving the participation of human subjects
in both treatment and prevention trials from both a plan-
ning and implementation perspective. We would also like
to generate activity on topics that have been relatively
neglected and that should be prioritized for future
research, including the very important subject of harm
reduction and how to persuade policy makers that imple-
mentation of certain strategies, that might not be per-
ceived as having popular support, could, in fact, result in
diminished rates of HIV transmission.
We will also solicit articles from major funding agencies
and key opinion leaders in various fields in regard to the
priorities that they might wish to set for research in devel-
oping country settings. As an example, invited articles will
be solicited from leaders at the National Institute of
Health, the Gates Foundation, the International Partner-
ship on Microbicides, and the International AIDS Vaccine
Initiative, among many others.
Journal of the International AIDS Society (JIAS) will closely
collaborate with other journals such as AIDS, Retrovirology
and AIDS Research and Therapy to serve the scientific com-
munity by disseminating a wide range of scientific find-
ings in the field. In the area of basic science research, we
hope to collaborate closely with our sister journal Retrovi-
rology. And it is conceivable that we may also decide, on
occasion, that a different sister journal may be more
appropriate for a manuscript submitted to JIAS. We will
remain as flexible as possible with decisions of this type.
Our goal is to transform JIAS into a highly rated and well
respected journal in which to publish high quality manu-
scripts. In order to realize this goal, we recognize that we
will have to work hard. At the same time, we will need to
be tough and only accept high quality manuscripts. This is
a necessary measure if we are to succeed in the realization
of our goals for JIAS and the promotion of high quality
research in HIV/AIDS from the world at large and devel-
oping countries in particular.
Journal of the International AIDS Society (JIAS) welcomes
submissions. We ask colleagues to submit via the online
submission tool. We look forward to reviewing and pub-
lishing exciting new data and research that advance the
struggle against the HIV pandemic.Page 2 of 2
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